The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
BUSINESS
Japan Grants 1st Conditional Approval to Terumo’s HeartSheet
Major Japanese medical device maker Terumo obtained conditional approval for its cell-based heart failure therapy, HeartSheet, the first such approval given in Japan since a new “regenerative medicine” category was created under the revised pharmaceutical affairs law. HeartSheet, autologous skeletal…
To read the full story
Related Article
- Japan Panel Says No to Full Approval of HeartSheet, Clears Breyanzi’s Broader Label
July 22, 2024
- Terumo Debuts Cell-Based Heart Failure Therapy HeartSheet
May 31, 2016
- Drug Pricing Organization to Price JCR’s Cell Therapy Temcell
October 1, 2015
- Terumo Aims at Annual Sales of 1-2 Billion Yen for HeartSheet within 5-10 Years
September 25, 2015
- PAFSC Committee Recommends Approval for 2 Regenerative Medicine Products
September 4, 2015
BUSINESS
- Toho Launches Specialty Drug Home Delivery Service with Vyvdura
May 13, 2025
- Bayer Files Eylea 8 mg for Macular Edema following RVO in Japan
May 13, 2025
- Lusefi Filed for Pediatric Use in Japan: Taisho
May 13, 2025
- J&J Taps Chris Rieger to Lead Japan Pharma Business
May 13, 2025
- Shionogi, Cilcare Ink Research Collab on Novel Hearing Loss Drugs
May 12, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…